Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 2,085 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open Label Extension Study Clear all

Conditions: Human Immunodeficiency Virus (HIV)-1 Infection
Interventions: Elvucitabine, Lamivudine, Emtricitabine; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Atlanta, Georgia • Cincinnati, Ohio

Conditions: Prostate Cancer
Interventions: Degarelix; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 17
States / cities: Homewood, Alabama • Anaheim, California • Tarzana, California + 14 more

Conditions: Parkinson's Disease (PD)
Interventions: ABBV-951; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 15
States / cities: Birmingham, Alabama • Sun City, Arizona • Aurora, Colorado + 12 more

Conditions: Atopic Dermatitis
Interventions: Tapinarof cream, 1%; Drug
Lead sponsor: Organon and Co; Industry
Eligibility: 2 Years and older
Enrollment: 728 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 102
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 88 more

Conditions: Sickle Cell Disease
Interventions: IMR-687; Drug
Lead sponsor: Imara, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 3
States / cities: Farmington, Connecticut • Hollywood, Florida • Temple, Texas

Conditions: ADHD
Interventions: Drug: PRC-063, PRC-063; Drug
Lead sponsor: Rhodes Pharmaceuticals, L.P.; Industry
Eligibility: 12 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 30
States / cities: Los Angeles, California • National City, California • Newport Beach, California + 25 more

Conditions: Adolescent Lupus Nephritis, Pediatric Lupus Nephritis
Interventions: voclosporin; Drug
Lead sponsor: Aurinia Pharmaceuticals Inc.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
Interventions: Tofersen, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 12
States / cities: Scottsdale, Arizona • La Jolla, California • San Francisco, California + 9 more

Conditions: Healthy
Interventions: Rilpivirine, Rilpivirine Long-acting Parenteral Formulation; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Urticaria Chronic
Interventions: Briquilimab; Drug
Lead sponsor: Jasper Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 10 more

Conditions: Multiple Myeloma
Interventions: Oprozomib, Lenalidomide, Dexamethasone, Cyclophosphamide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 14
States / cities: Huntsville, Alabama • Burbank, California • Los Angeles, California + 11 more

Conditions: Dup15q Syndrome
Interventions: Basmisanil, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 14 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Los Angeles, California • Chicago, Illinois

Conditions: Rhinoplasty
Interventions: Polydioxanone (PDS) plates, Caudal septal extension graft performed through endonasal rhinoplasty; Device · Procedure
Lead sponsor: DeNova Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Carcinoid Syndrome
Interventions: Telotristat etiprate, Placebo-matching telotristat etiprate; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 17
States / cities: Mobile, Alabama • Palo Alto, California • San Francisco, California + 13 more

Conditions: Ulcerative Colitis
Interventions: abatacept (ABA), placebo, abatacept; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 50
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 43 more

Conditions: Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy
Interventions: SBR759, Sevelamer HCl; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 19
States / cities: Chula Vista, California • La Mesa, California • Whittier, California + 16 more

Conditions: Gastroparesis, Opioid Use
Interventions: Naloxegol 25 MG Oral Tablet [Movantik], Placebo Oral Tablet; Drug
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 84 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Arthritis, Rheumatoid
Interventions: peficitinib; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 20
States / cities: Birmingham, Alabama • La Jolla, California • Palm Desert, California + 17 more

Conditions: Plaque Psoriasis
Interventions: tapinarof cream, 1%; Drug
Lead sponsor: Organon and Co; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 763 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 85
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 74 more

Conditions: Alzheimer Disease
Interventions: SNK01; Biological
Lead sponsor: NKGen Biotech, Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Glendale, California

Conditions: Parkinson's Disease Psychosis
Interventions: Pimavanserin tartrate (ACP-103); Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 83
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 80 more

Conditions: Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost; Drug
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Artesia, California • Newport Beach, California + 6 more

Conditions: Hypercholesterolemia
Interventions: LIB003; Drug
Lead sponsor: LIB Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Cincinnati, Ohio

Conditions: Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Interventions: treprostinil SMI (treprostinil inhalation spray); Combination Product
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2034
U.S. locations: 15
States / cities: Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 11 more

Search by objective public record fields.

Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A

Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia

Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD

Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis

Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms

A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma

A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome

Safety and Efficacy Study of Polydioxanone (PDS) Plates in Rhinoplasty

TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)

A Study of Abatacept in Patients With Active Ulcerative Colitis

Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis

Naloxegol for Opioid-Related Gastroparesis

A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study

Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)

Open-Label Extension Protocol to SNK01-AD01 Study

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert

Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003

An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)